Trial · NCT00991029

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

NCT00991029, Phase 3, Terminated, University of California, San Francisco; results first posted 2018-12-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. Trials, record NCT00991029. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00991029

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
NCT number: NCT00991029
Status: Terminated
Phases: Phase 3
Enrollment: 4,881 participants, actual
Lead sponsor: University of California, San Francisco
Conditions: Ischemic Attack, Transient
Interventions: Clopidogrel, placebo
First posted: 2009-10-07
Last updated: 2018-12-04
Results first posted: 2018-12-04

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes	Up to 90 days	Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes
Primary	Major Hemorrhage	Up to 90 days	Primary safety outcome: Number of Participants with major hemorrhage
Secondary	Ischemic Stroke	Up to 90 days	Secondary efficacy outcome:Number of participants with Ischemic stroke
Secondary	Myocardial Infarction	Up to 90 days	Secondary efficacy outcome: Number of participants with Myocardial infarction
Secondary	Death From Ischemic Vascular Causes	Up to 90 days	Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes
Secondary	Ischemic or Hemorrhagic Stroke	Up to 90 days	Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke
Secondary	Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage	Up to 90 days	Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage
Other	Hemorrhagic Stroke	up to 90 days	Other safety outcome: Number of participants with Hemorrhagic stroke
Other	Symptomatic Intracerebral Hemorrhage	up to 90 days	Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage
Other	Other Symptomatic Intracranial Hemorrhage	up to 90 days	Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage

1 to 10 of 13Source ClinicalTrials.gov

See all 13 registered outcomes

Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes	Up to 90 days	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Major Hemorrhage	Up to 90 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Ischemic Stroke	Up to 90 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Myocardial Infarction	Up to 90 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Death From Ischemic Vascular Causes	Up to 90 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Ischemic or Hemorrhagic Stroke	Up to 90 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage	Up to 90 days	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Hemorrhagic Stroke	up to 90 days	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Symptomatic Intracerebral Hemorrhage	up to 90 days	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Other Symptomatic Intracranial Hemorrhage	up to 90 days	Participants	COUNT_OF_PARTICIPANTS

1 to 10 of 13Source ClinicalTrials.gov

See all 13 outcomes

Results by group26

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes	Clopidogrel	121	Participants
Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes	Placebo	160	Participants
Major Hemorrhage	Clopidogrel	23	Participants
Major Hemorrhage	Placebo	10	Participants
Ischemic Stroke	Clopidogrel	112	Participants
Ischemic Stroke	Placebo	155	Participants
Myocardial Infarction	Clopidogrel	10	Participants
Myocardial Infarction	Placebo	7	Participants
Death From Ischemic Vascular Causes	Clopidogrel	6	Participants
Death From Ischemic Vascular Causes	Placebo	4	Participants

1 to 10 of 26Source ClinicalTrials.gov

See all 26 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Clopidogrel	2,432
Overall Study	STARTED	Placebo	2,449
Overall Study	COMPLETED	Clopidogrel	2,276
Overall Study	COMPLETED	Placebo	2,281
Overall Study	NOT COMPLETED	Clopidogrel	156
Overall Study	NOT COMPLETED	Placebo	168

Source ClinicalTrials.gov

Adverse events560

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Acute myocardial infarction	Cardiac disorders	Clopidogrel	0	2,432	0
other	Acute myocardial infarction	Cardiac disorders	Placebo	1	2,449	1
other	Cerebral amyloid angiopathy	Nervous system disorders	Clopidogrel	1	2,432	1
other	Cerebral amyloid angiopathy	Nervous system disorders	Placebo	0	2,449	0
other	Cerebrovascular accident	Nervous system disorders	Clopidogrel	3	2,432	3
other	Cerebrovascular accident	Nervous system disorders	Placebo	4	2,449	4
other	Conjunctival haemorrhage	Eye disorders	Clopidogrel	0	2,432	0
other	Conjunctival haemorrhage	Eye disorders	Placebo	1	2,449	1
other	Contusion	Injury, poisoning and procedural complications	Clopidogrel	7	2,432	7
other	Contusion	Injury, poisoning and procedural complications	Placebo	1	2,449	1

1 to 10 of 560Source ClinicalTrials.gov

See all 560 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Clopidogrel	18	2,432
Total, all-cause mortality	Placebo	12	2,449
Total, other adverse events	Clopidogrel	89	2,432
Total, other adverse events	Placebo	84	2,449
Total, serious adverse events	Clopidogrel	382	2,432
Total, serious adverse events	Placebo	382	2,449

Source ClinicalTrials.gov

Papers63

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
2349586	BACKGROUND	PubMed
2648650	BACKGROUND	PubMed
3590245	BACKGROUND	PubMed
4038103	BACKGROUND	PubMed
4690325	BACKGROUND	PubMed
7303066	BACKGROUND	PubMed
9756590	BACKGROUND	PubMed
10582972	BACKGROUND	PubMed
11147987	BACKGROUND	PubMed
11387488	BACKGROUND	PubMed

1 to 10 of 63

See all 63 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons15

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Clopidogrel vs Placebo: Major Hemorrhage Other Than Intracranial Hemorrhage	Trial comparisons
Clopidogrel vs Placebo: Symptomatic Intracerebral Hemorrhage	Trial comparisons
Clopidogrel vs Placebo: Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes	Trial comparisons
Clopidogrel vs Placebo: Myocardial Infarction	Trial comparisons
Clopidogrel vs Placebo: Minor Hemorrhage	Trial comparisons
Clopidogrel vs Placebo: Death From Ischemic Vascular Causes	Trial comparisons
Clopidogrel vs Placebo: Hemorrhagic Stroke	Trial comparisons
Clopidogrel vs Placebo: Other Symptomatic Intracranial Hemorrhage	Trial comparisons
Clopidogrel vs Placebo: Death From Any Cause	Trial comparisons
Clopidogrel vs Placebo: Ischemic Stroke	Trial comparisons

1 to 10 of 15

See all 15 trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00991029

GET https://conductscience.org/api/trials/v1/NCT00991029/results?page=2

API reference For AI assistants